ENDRA Life Sciences (Nasdaq: NDRA) shares Q2 2026 earnings update

Q: What did ENDRA Life Sciences (NDRA) announce on August 17, 2026?

ENDRA Life Sciences announced that it issued a press release on August 17, 2026 detailing its financial results for the quarter ended June 30, 2026 , and made that release available as Exhibit 99.1 to its Form 8-K.

Q: Which period do the reported financial results for NDRA cover?

The reported financial results for NDRA cover the quarter ended June 30, 2026 . The company disclosed that these quarterly results are summarized in a press release furnished as Exhibit 99.1 to the Form 8-K dated August 17, 2026.

Q: Is ENDRA Life Sciences’ Exhibit 99.1 considered filed or furnished?

Exhibit 99.1 is being furnished, not filed , under Item 2.02. As furnished information, it is not subject to the liabilities of Section 18 of the Exchange Act and is only incorporated by reference if specifically stated elsewhere.

Q: On which exchange is ENDRA Life Sciences (NDRA) common stock listed?

ENDRA Life Sciences’ common stock is listed on The Nasdaq Stock Market LLC under the trading symbol NDRA . The company identifies its security as common stock with a par value of $0.0001 per share .

Q: What exhibits accompany ENDRA Life Sciences’ August 17, 2026 Form 8-K?

The Form 8-K includes Exhibit 99.1 , a press release dated August 17, 2026, and Exhibit 104 , the Cover Page Interactive Data File embedded within the Inline XBRL document, as listed under Item 9.01(d).

Filing Impact

(High)

Filing Sentiment

(Neutral)

Form Type

425

Rhea-AI Filing Summary

ENDRA Life Sciences Inc. reported that it released a press release on August 17, 2026 announcing its financial results for the quarter ended June 30, 2026. The press release is provided as Exhibit 99.1 to this Form 8-K and is being furnished rather than filed, which limits its treatment under Section 18 of the Exchange Act. The company’s common stock, par value $0.0001 per share, trades under the symbol NDRA on The Nasdaq Stock Market LLC.

Insights

Analyzing...

Key Figures

Quarter end date: June 30, 2026 Report date: August 17, 2026 Par value per share: $0.0001 per share +2 more

5 metrics

Quarter end date June 30, 2026 Financial results period referenced in the press release

Report date August 17, 2026 Date the company issued the press release and Form 8-K

Par value per share $0.0001 per share Par value of ENDRA Life Sciences common stock

Commission File Number 001-37969 SEC registration reference for the company

IRS Employer Identification No. 26-0579295 Federal tax identification number for the registrant

Key Terms

Emerging growth company, Section 18 of the Securities Exchange Act of 1934, Inline XBRL, Exhibit 99.1

4 terms

Emerging growth company regulatory

"Emerging growth company"

An emerging growth company is a recently public or smaller public firm that qualifies for temporary, lighter regulatory and disclosure rules to reduce the cost and effort of being public. For investors, it means the company may provide less historical financial detail and face fewer reporting requirements than larger firms, so it can grow more quickly but also carries higher uncertainty—like buying a promising early-stage product with fewer user reviews.

Section 18 of the Securities Exchange Act of 1934 regulatory

"shall not be deemed “filed” for purposes of Section 18 of the Securities"

Inline XBRL technical

"Cover Page Interactive Data File (embedded within the Inline XBRL document)"

Inline XBRL is a file format for financial filings that embeds machine-readable data tags directly inside the human-readable report, so the same document can be read by people and parsed by software. For investors it makes extracting, comparing and verifying financial numbers faster and more reliable—like a grocery list where each item also has a barcode—reducing manual errors and speeding up analysis.

Exhibit 99.1 regulatory

"Press Release dated August 17, 2026, furnished herewith"

Exhibit 99.1 is a label used in regulatory filings to identify a specific attached document, most often a company press release or investor presentation filed with securities regulators. For investors it matters because it marks an official, contemporaneous source of information directly tied to a filing—like the original news article pinned to a legal record—so traders and analysts treat it as an authoritative statement that can move a stock or clarify a company’s situation.

Earnings Snapshot

quarter ended June 30, 2026

FAQ

What did ENDRA Life Sciences (NDRA) announce on August 17, 2026?

ENDRA Life Sciences announced that it issued a press release on August 17, 2026 detailing its financial results for the quarter ended June 30, 2026, and made that release available as Exhibit 99.1 to its Form 8-K.

Which period do the reported financial results for NDRA cover?

The reported financial results for NDRA cover the quarter ended June 30, 2026. The company disclosed that these quarterly results are summarized in a press release furnished as Exhibit 99.1 to the Form 8-K dated August 17, 2026.

Is ENDRA Life Sciences’ Exhibit 99.1 considered filed or furnished?

Exhibit 99.1 is being furnished, not filed, under Item 2.02. As furnished information, it is not subject to the liabilities of Section 18 of the Exchange Act and is only incorporated by reference if specifically stated elsewhere.

On which exchange is ENDRA Life Sciences (NDRA) common stock listed?

ENDRA Life Sciences’ common stock is listed on The Nasdaq Stock Market LLC under the trading symbol NDRA. The company identifies its security as common stock with a par value of $0.0001 per share.

Who signed the August 17, 2026 Form 8-K for ENDRA Life Sciences (NDRA)?

The Form 8-K dated August 17, 2026 was signed on behalf of ENDRA Life Sciences by Richard Jacroux, who is identified as the company’s Chief Financial Officer, acting as a duly authorized officer of the registrant.

What exhibits accompany ENDRA Life Sciences’ August 17, 2026 Form 8-K?

The Form 8-K includes Exhibit 99.1, a press release dated August 17, 2026, and Exhibit 104, the Cover Page Interactive Data File embedded within the Inline XBRL document, as listed under Item 9.01(d).

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google

Available on EDGAR 08/17/2026 - 04:36 PM Accepted by SEC EDGAR 08/17/2026 - 04:07 PM

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, DC 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported) August 17, 2026

ENDRA Life Sciences Inc.

(Exact name of registrant as specified in its charter)

Delaware		001-37969		26-0579295
(State or other jurisdiction of incorporation)		(Commission File Number)		(IRS Employer Identification No.)

3600 Green Court, Suite 350 Ann Arbor, MI		48105
(Address of principal executive offices)		(Zip Code)

Registrant's telephone number, including area code		(734) 335-0468

(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

☒	Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐	Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐	Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐	Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class		Trading Symbol(s)		Name of each exchange on which registered
Common stock, par value $0.0001 per share		NDRA		The Nasdaq Stock Market LLC

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 2.02 Results of Operations and Financial Condition

On August 17, 2026, ENDRA Life Sciences Inc. (the “Company”) issued a press release announcing its financial results for the quarter ended June 30, 2026. A copy of the press release is being furnished as Exhibit 99.1 to this Current Report on Form 8-K.

The information in Item 2.02 of this Current Report on Form 8-K and Exhibit 99.1 attached hereto is intended to be furnished and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934 (the “Exchange Act”) or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933 or the Exchange Act, except as expressly set forth by specific reference in such filing.

Item 9.01 Financial Statements and Exhibits.

(d) Exhibits

Exhibit No.		Description

99.1		Press Release dated August 17, 2026, furnished herewith.
104		Cover Page Interactive Data File (embedded within the Inline XBRL document).

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

	ENDRA Life Sciences Inc.
August 17, 2026
	By:	/s/ Richard Jacroux
	Name:	Richard Jacroux
	Title:	Chief Financial Officer

Source: View Original Filing on SEC EDGAR